Ambu maintains its full-year outlook following a Q2 in which revenue totaled DKK 1bn.
However, the firm underperformed revenue-wise compared the DKK 1.016bn that analysts had expected. Ambu only provided DKK 1.001bn (USD 163.3m) in the second quarter of the company's staggered fiscal year. However, this is still progress compared to the DKK 989m from the same time period last year.
Get full access for you and your coworkers.
Start a free company trial todayAlready a member? Log in.
More from MedWatch
More disappointment for Orphazyme as FDA rejects Niemann Pick C application
The FDA have rejected an application for marketing authorization for Orphazyme's main drug candidate, arimoclomol, as a treatment for metabolic disease Niemann Pick C. The authority wants more data.
Orphazyme CEO silent on potential firings in wake of FDA rejection
The FDA rejection of Orphazyme's drug candidate in its main indication will trigger major cuts at the biotech firm, but CEO Christophe Bourdon has no comment on where they will be implemented and how hard the US organization will be hit.
Orphazyme cuts guidance following FDA setback
Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.
Top Orphazyme figure on FDA rejection: "It is very disappointing and very unexpected"
Biotech heavyweight Bo Jesper Hansen is very disappointed over the FDA rejection of Orphazyme's only drug candidate.
US OTC hearing aid channel back on Department of Health agenda
The US health department aims to have a hearing on publishing the regulatory framework for selling hearing aids over the course of the year.
eTMF Manager - Klifo 
(Senior) Regulatory Science Specialist - IWA Consulting 
Associate Medical Director, Clinical Development, Y-mAbs Therapeutics 
Senior Contract Manager - Genmab 
Chief Physician - Clinical Innovation Centre, Novo Nordisk 
Drug Safety Advisor - ALK 
Analytical Coordinator (Senior scientist) – Permanent position, Symphogen 
Regulatory affairs life cycle specialist 
Senior Clinical Development Scientist/Physician - Lundbeck